Company news
Correvio Pharma Corp news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Correvio Announces Brinavess Eligibility for Patent Extension
October 29, 2018
Correvio Announces Intention to Re-File Brinavess® NDA in Second Quarter 2019
October 23, 2018
Correvio to Participate In Upcoming Investor Conferences
September 20, 2018
Correvio Reports Preliminary Data Collected from >2,000 Brinavess® Treatment Episodes in EU Post-Authorization Safety Study
September 5, 2018
Correvio Highlights Completion of SteadyMed Acquisition by United Therapeutics
September 4, 2018
Correvio to Participate in Upcoming Investor Conferences
August 28, 2018
Correvio Announces EU Survey Data Demonstrating Brinavess Successfully Avoided Hospitalization in 85% of Patients
August 16, 2018
Correvio Reports Second Quarter 2018 Financial Results
August 14, 2018
Correvio Announces Brinavess® Selected as Potentially Eligible for Priority Review in China
August 14, 2018
Correvio To Report Second Quarter 2018 Financial Results On August 14, 2018
August 7, 2018
Correvio to present at the Canaccord Genuity 38th Annual Growth Conference
August 1, 2018
Correvio Announces At The Market Offering
July 10, 2018
Correvio Provides U.S. Regulatory Update for BRINAVESS
June 11, 2018
Brinavess Data Receives Top Award For Best Article Published In The Spanish Medical Journal EMERGENCIAS
June 6, 2018
Correvio Pharma Corp, Formerly Cardiome Pharma Corp, Announces Stock Ticker Symbol Change to CORV
May 17, 2018
Correvio Reports First Quarter 2018 Financial Results
May 15, 2018
Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals
May 15, 2018
Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call
May 10, 2018
Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 26, 2018
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®
April 17, 2018
Cardiome Announces Fifteen Xydalba(TM) and Zevtera® Abstracts at ECCMID 2018
April 12, 2018
Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds
April 6, 2018
Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission
April 2, 2018
Cardiome Announces Recent Insider Purchases
March 28, 2018
Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review
March 22, 2018
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome
March 20, 2018
Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results
March 13, 2018
Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13
March 6, 2018
Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare Conference
February 8, 2018
Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen
January 23, 2018
Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit
January 10, 2018
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
December 12, 2017
Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission
December 11, 2017
Cardiome Announces Xydalba(TM) Treatment And Patient Experience Presentations At The 2017 National Opat Conference
December 11, 2017
Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 20, 2017
Cardiome Reports Third Quarter 2017 Financial Results
November 14, 2017
Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14
November 7, 2017
Cardiome Announces Expansion of Global Geographic Footprint for Brinavess®
November 2, 2017
Cardiome Announces Commercial Launch of Xydalba(TM) in Three New European Geographies
October 30, 2017
Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel
September 12, 2017
Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 5, 2017
New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BRINAVESS®
August 30, 2017
Cardiome Provides U.S. Regulatory Update For BRINAVESS
August 21, 2017
Cardiome Reports Second Quarter 2017 Financial Results
August 8, 2017
Cardiome To Hold Second Quarter 2017 Financial Results Conference Call On August 8
August 1, 2017
Cardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen
July 17, 2017
Cardiome's Partner SteadyMed Submits U.S. New Drug Application for TREVYENT® for the Treatment of Pulmonary Arterial Hypertension
July 3, 2017
Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel
June 21, 2017
Cardiome Announces Commercial Launch of BRINAVESS® (Vernakalant Hydrochloride) in Canada
June 12, 2017
Cardiome Reports Changes To Senior Management Team
May 16, 2017
Decks
- Q3 2019 Earnings Presentation
Earnings · 14 slides · Nov 14, 2019
- Investor Presentation (November 2019)
Investor deck · 14 slides · November 2019